MERCKíS FOSAMAX GAINS FDA CLEARANCE TO PREVENT OSTEOPOROSIS
Ogilvy Adams & RinehartWEST POINT, Pa., April 28, 1997 -- Merck & Co., Inc. today announced that the U.S. Food and Drug Administration (FDA) has cleared its drug Fosamax"š (alendronate sodium) to prevent osteoporosis in postmenopausal women. Fosamax is now one of the few drugs indicated to prevent a chronic disease. In addition, Fosamax was cleared to prevent fractures in postmenopausal women with osteoporosis. The FDA's decision to clear Fosamax for prevention of the bone-thinning disease gives millions of postmenopausal women in the United States and their physicians a nonhormonal option for preventing rapid bone loss in the early postmenopausal period; bone loss may lead to osteoporosis and its fractures.